HCA Healthcare, Inc.: Form 10-Q for the period ended Mar 31, 2024
Filed with the SEC on May 2, 2024 and accepted by EDGAR at May 2, 2024, 16:30 ET.
Management's discussion and analysis
As filed, 1,821 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
During January 2024 and January 2023, our Board of Directors authorized share repurchase programs for up to $6 billion and $3 billion, respectively, of our outstanding common stock. During the quarter ended March 31, 2024, we repurchased 3,893,746 shares of our common stock at an average price of $303.06 per share through market purchases pursuant to the January 2023 authorization (which was completed during the first quarter of 2024) and the January 2024 authorization. At March 31, 2024, we had $5.595 billion of repurchase authorization available under the January 2024 authorization.
The following table provides certain information with respect to our repurchases of common stock from January 1, 2024 through March 31, 2024 (dollars in billions, except per share amounts).
| Period | Total Number of Shares Purchased | Average Price Paid per Share | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs | Approximate Dollar Value of Shares That May Yet Be Purchased Under Publicly Announced Plans or Programs |
|---|---|---|---|---|
| January 2024 | 1,426,082 | $280.50 | 1,426,082 | $6.375 |
| February 2024 | 1,227,827 | $309.50 | 1,227,827 | $5.995 |
| March 2024 | 1,239,837 | $322.63 | 1,239,837 | $5.595 |
| Total for first quarter 2024 | 3,893,746 | $303.06 | 3,893,746 |
On April 25, 2024, our Board of Directors declared a quarterly dividend of $0.66 per share on our common stock payable on June 28, 2024 to stockholders of record at the close of business on June 14, 2024. Future declarations of quarterly dividends and the establishment of future record and payment dates are subject to the final determination of our Board of Directors. Our ability to declare future dividends may also from time to time be limited by the terms of our debt agreements.
Market risk
As filed, 186 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The information called for by this item is provided under the caption “Market Risk” under Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”
Controls and procedures
As filed, 727 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
HCA’s management, with the participation of HCA’s chief executive officer and chief financial officer, has evaluated the effectiveness of HCA’s disclosure controls and procedures as of March 31, 2024. Based on that evaluation, HCA’s chief executive officer and chief financial officer concluded that HCA’s disclosure controls and procedures were effective as of March 31, 2024.
Changes in Internal Control Over Financial Reporting
During the period covered by this report, there have been no changes in our internal control over financial reporting that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.
Risk factors
As filed, 448 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Reference is made to the factors set forth under the caption “Forward-Looking Statements” in Part I, Item 2 of this quarterly report on Form 10-Q and other risk factors described in our annual report on Form 10-K for the year ended December 31, 2023, which are incorporated herein by reference. There have not been any material changes to the risk factors previously disclosed in our annual report on Form 10-K for the year ended December 31, 2023.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2024-01-01 to 2024-03-31 | $17.34bn | us-gaap:Revenues |
| Interest expense | 3 months2024-01-01 to 2024-03-31 | $512.0m | us-gaap:InterestExpense |
| Income tax | 3 months2024-01-01 to 2024-03-31 | $445.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2024-01-01 to 2024-03-31 | $1.59bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-01-01 to 2024-03-31 | $5.93 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-01-01 to 2024-03-31 | $6.01 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-01-01 to 2024-03-31 | 268,016,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2024-01-01 to 2024-03-31 | $2.47bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2024-01-01 to 2024-03-31 | $1.12bn | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 3 months2024-01-01 to 2024-03-31 | $185.0m | us-gaap:PaymentsOfDividends |
| Share repurchases | 3 months2024-01-01 to 2024-03-31 | $1.18bn | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2024-03-31 | $1.28bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-03-31 | $15.28bn | us-gaap:AssetsCurrent |
| Total assets | At period end2024-03-31 | $56.96bn | us-gaap:Assets |
| Current liabilities | At period end2024-03-31 | $13.14bn | us-gaap:LiabilitiesCurrent |
| Long-term debt | At period end2024-03-31 | $37.16bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2024-03-31 | $3.03bn | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2024-03-31 | −$1.61bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-24-052195. Last ingested by Listed: Oct 29, 2026, 18:36 ET. Listed shows no prices and gives no investment advice.